Traxoprodil is primarily researched for its potential application in the treatment of neurological disorders, particularly those involving excitotoxicity, such as stroke and traumatic brain injury. It functions as a selective antagonist of the NR2B subunit of NMDA receptors, which are implicated in the regulation of synaptic plasticity and memory function. By blocking these receptors, Traxoprodil may help reduce neuronal damage caused by excessive glutamate release, a common issue in ischemic conditions. Additionally, its neuroprotective properties are being explored for potential use in managing chronic pain and neurodegenerative diseases like Alzheimer's and Parkinson's. Ongoing studies aim to evaluate its efficacy and safety in clinical settings.